Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
780 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01674842 | Cisplatin + RT for Triple Negative Breast Cancer | completed | Phase 1 | 55 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 25, 2021 | clinicaltrials |
| NCT02639208 | Novel Social Media Intervention For Older Br CA Patients | completed | N/A | 47 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 20, 2021 | clinicaltrials |
| NCT01574937 |
| XL-184+Abiraterone in Post-Chemo CRPC |
| completed |
| Phase 1 |
| 27 |
| Dana-Farber Cancer InstituteOTHER |
| 1 |
| Aug 6, 2021 |
| clinicaltrials |
| NCT03316599 | Study of Gemcitabine, Nab-paclitaxel, and Ficlatuzumab (AV-299) in Patients With Advanced Pancreatic Cancer | completed | Phase 1 | 26 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 3, 2021 | clinicaltrials |
| NCT02706249 | Study Of Weight-Based Versus Standard Dose Enoxaparin Thromboprophylaxis In High-Risk Hospitalized Cancer Patients | completed | Phase 2 | 50 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 8, 2021 | clinicaltrials |
| NCT02164240 | Phase Ib Study of SUnitinib Alternating With REgorafenib in Patients With Metastatic and/or Unresectable GIST(SURE) | completed | Phase 1 | 14 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 14, 2021 | clinicaltrials |
| NCT03447886 | Understanding Barriers to Initiation and Adherence to Endocrine Therapy in Young Breast Cancer Survivors of Diverse Backgrounds | completed | — | 17 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 11, 2021 | clinicaltrials |
| NCT02260531 | Cabozantinib +/- Trastuzumab In Breast Cancer Patients w/ Brain Metastases | completed | Phase 2 | 36 | Dana-Farber Cancer InstituteOTHER | 1 | May 20, 2021 | clinicaltrials |
| NCT02581384 | Stereotactic Body Radiotherapy (SBRT) for Pulmonary Metastases in Ewing Sarcoma, Rhabdomyosarcoma, and Wilms Tumors | terminated | Phase 1 / Phase 2 | 5 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 30, 2021 | clinicaltrials |
| NCT03051672 | Phase II PEMBROLIZUMAB + PALLIATIVE RADIOTHERAPY IN BC | terminated | Phase 2 | 8 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 27, 2021 | clinicaltrials |
| NCT01125293 | Everolimus, Bortezomib and/or Rituximab in Patients With Relapsed/Refractory Waldenstrom's Macroglobulinemia | terminated | Phase 1 / Phase 2 | 46 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 23, 2021 | clinicaltrials |
| NCT02041429 | Ruxolitinib W/ Preop Chemo For Triple Negative Inflammatory Brca | completed | Phase 1 / Phase 2 | 20 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 21, 2021 | clinicaltrials |
| NCT03495323 | A Study of Prexasertib (LY2606368), CHK1 Inhibitor, and LY3300054, PD-L1 Inhibitor, in Patients With Advanced Solid Tumors | completed | Phase 1 | 17 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 15, 2021 | clinicaltrials |
| NCT00258687 | Vaccine Trial for Clear Cell Sarcoma, Pediatric Renal Cell Carcinoma, Alveolar Soft Part Sarcoma and Children With Stage IV Melanoma | completed | Phase 1 | 12 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 3, 2021 | clinicaltrials |
| NCT01623349 | Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer | completed | Phase 1 | 118 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 10, 2021 | clinicaltrials |
| NCT02127359 | Whole-Exome Sequencing (WES) of Cancer Patients | completed | — | 244 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 10, 2021 | clinicaltrials |
| NCT00936611 | LBH589 in Relapsed or Relapsed and Refractory Waldenstrom's Macroglobulinemia | completed | Phase 2 | 39 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 28, 2021 | clinicaltrials |
| NCT02514824 | MLN0128 in Recurrent/Metastatic Merkel Cell Carcinoma | completed | Phase 1 / Phase 2 | 9 | Dana-Farber Cancer InstituteOTHER | 1 | Dec 29, 2020 | clinicaltrials |
| NCT02337491 | Pembrolizumab +/- Bevacizumab for Recurrent GBM | completed | Phase 2 | 80 | Dana-Farber Cancer InstituteOTHER | 1 | Dec 22, 2020 | clinicaltrials |
| NCT04119869 | Smart Phone App Intervention In Young Adults With Cancer | completed | N/A | 25 | Dana-Farber Cancer InstituteOTHER | 1 | Dec 8, 2020 | clinicaltrials |
| NCT03993210 | The Value of Advanced MR Imaging in Gynecological Tumors and Benign Uterine Fibroids | terminated | N/A | 1 | Dana-Farber Cancer InstituteOTHER | 1 | Dec 2, 2020 | clinicaltrials |
| NCT00301093 | Vaccine Therapy and Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia | completed | Phase 1 | 3 | Dana-Farber Cancer InstituteOTHER | 1 | Oct 28, 2020 | clinicaltrials |
| NCT03279055 | Web-based Insomnia Treatment for Adolescent and Young Adult Cancer Survivors | completed | N/A | 22 | Dana-Farber Cancer InstituteOTHER | 1 | Oct 28, 2020 | clinicaltrials |
| NCT00422799 | Combination Bortezomib and Rituximab in Patients With Waldenstrom's Macroglobulinemia (WM) | completed | Phase 2 | 63 | Dana-Farber Cancer InstituteOTHER | 1 | Oct 27, 2020 | clinicaltrials |
| NCT03846583 | Tucatinib + Abemaciclib + Herceptin for HER2+ MBC | withdrawn | Phase 1 | 0 | Dana-Farber Cancer InstituteOTHER | 0 | Oct 23, 2020 | clinicaltrials |
| NCT01663090 | Ferumoxytol-Enhanced MRI in Adult/Pedi Sarcomas | withdrawn | N/A | 0 | Dana-Farber Cancer InstituteOTHER | 1 | Oct 19, 2020 | clinicaltrials |
| NCT03576872 | The GI Binder: A Psychoeducational Intervention for Gastrointestinal Cancer Patients | completed | N/A | 49 | Dana-Farber Cancer InstituteOTHER | 1 | Oct 19, 2020 | clinicaltrials |
| NCT00442130 | Reduced Intensity Stem Cell Transplantation for Chronic Lymphocytic Leukemia Followed by Vaccination | completed | Phase 1 | 27 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 17, 2020 | clinicaltrials |
| NCT00809250 | Vaccination With GM-K562 Cells in Patients With Advanced Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) After Allogeneic Hematopoetic Stem Cell Transplantation | completed | Phase 1 | 33 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 16, 2020 | clinicaltrials |
| NCT02201212 | Everolimus for Cancer With TSC1 or TSC2 Mutation | completed | Phase 2 | 30 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 16, 2020 | clinicaltrials |
| NCT02400437 | Trial of Ixazomib, Dexamethasone and Rituximab in Patients With Untreated Waldenstrom's Macroglobulinemia | completed | Phase 2 | 26 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 2, 2020 | clinicaltrials |
| NCT03469258 | Study of Pancreatic Enzyme Replacement on Completion of Adjuvant Chemotherapy for Resected Pancreatic Adenocarcinoma | terminated | Phase 2 | 4 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 3, 2020 | clinicaltrials |
| NCT01647607 | Young and Strong: An Education and Supportive Care Intervention Study for Young Women With Breast Cancer(Y&S) | completed | N/A | 467 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 29, 2020 | clinicaltrials |
| NCT00576680 | RAD001 and Temozolomide in Patients With Advanced Pancreatic Neuroendocrine Tumors | completed | Phase 1 / Phase 2 | 43 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 9, 2020 | clinicaltrials |
| NCT02644382 | Improving Surgical Decision-making in Young Women With Breast Cancer | completed | — | 145 | Dana-Farber Cancer InstituteOTHER | 0 | Jun 29, 2020 | clinicaltrials |
| NCT00903968 | Combination Plerixafor (AMD3100)and Bortezomib in Relapsed or Relapsed/Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 58 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 2, 2020 | clinicaltrials |
| NCT01959542 | Early Changes In Multiparametric MRI In Prostate Cancer | completed | N/A | 15 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 2, 2020 | clinicaltrials |
| NCT02441140 | Detection of Tumor Associated Cell-free DNA in Peritoneal Fluid Obtained by Culdocentesis | terminated | N/A | 5 | Dana-Farber Cancer InstituteOTHER | 1 | May 4, 2020 | clinicaltrials |
| NCT03093272 | A Study of Docetaxel + ARN-509 in Castration-Resistant Prostate Cancer | terminated | Phase 2 | 9 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 9, 2020 | clinicaltrials |
| NCT00428233 | Banking of Chronic Lymphocytic Leukemia Tumor Cells for Vaccine Generation | completed | Phase 1 | 65 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 8, 2020 | clinicaltrials |
| NCT00137800 | Study of OSI-774 (Tarceva) in Previously Untreated Elderly Lung Cancer Patients | completed | Phase 2 | 82 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 3, 2020 | clinicaltrials |
| NCT03234933 | Post-Operative Ambulatory Challenge and Exercise (PACE) Trial | completed | N/A | 27 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 3, 2020 | clinicaltrials |
| NCT02018107 | PET/CT-Assessment of Liver Tumor Ablation | completed | N/A | 33 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 26, 2020 | clinicaltrials |
| NCT03331406 | Physical Activity In Gastrointestinal Cancer | completed | N/A | 20 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 12, 2020 | clinicaltrials |
| NCT02406521 | Exploratory Study of Radium-223 and VEGF-Targeted Therapy in Patients With Metastatic Renal Cell Carcinoma and Bone Mets | completed | Phase 1 | 30 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 4, 2020 | clinicaltrials |
| NCT02287519 | Sexual Therapy and Rehabilitation After Treatment for Ovarian Cancer (START-OC): A Pilot Intervention(START-OC) | completed | N/A | 53 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 28, 2020 | clinicaltrials |
| NCT03505372 | Role of Contrast Enhanced Spectral Mammography to Predict Upgrade Rates of Biopsy Proven Atypical Ductal Hyperplasia | terminated | N/A | 5 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 11, 2020 | clinicaltrials |
| NCT01747551 | FOLFOX +/- Ziv-Aflibercept for Esophageal and Gastric Cancer | completed | Phase 2 | 64 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 10, 2020 | clinicaltrials |
| NCT04007588 | A Phase II Trial of Neoadjuvant Treatment With PD-1 Inhibition (Nivolumab) With or Without IDO Inhibition (BMS-986205) and With or Without CTLA-4 Inhibition (Ipilimumab) in Resectable Stage III or IV Melanoma | withdrawn | Phase 2 | 0 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 5, 2020 | clinicaltrials |
| NCT04043845 | ERK 1/2 Signaling in Ibrutinib Resistant B-cell Malignancies | withdrawn | Phase 1 | 0 | Dana-Farber Cancer InstituteOTHER | 0 | Feb 5, 2020 | clinicaltrials |
Data updated 24 days agoSource updated unknownsource: clinicaltrials